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Background: Anaplastic thyroid cancer (ATC) is an aggressive malignant tumour with a poor prognosis. The
median overall survival is described in the literature to be just 6 months, however, in series of selected patients
treated by multimodal therapy cases of long-time-survival have been reported. We analyzed the role of radiotherapy
and the impact of other therapies and clinical features on survival in patients with ATC.
Methods: In a retrospective analysis of all patients (n = 40), who presented with histologically proven ATC at a
single centre between 1989 and 2008, patient and treatment characteristics with a focus on details of radiotherapy
were registered and the survival status determined.
Results: 39 of 40 patients received radiotherapy, 80% underwent surgery and 15% had chemotherapy. The median
dosis of radiation was 50 Gy (6–60.4 Gy), in 87.5% fractionation was once daily. In 49.4% opposing-field techniques
were applied, in 14% 3D-conformal-techniques and 32.5% combinations of both.
The median overall survival (OS) was 5 months, 1-year survival 35.2% and 5-year-survival 21.6%. Interestingly, 24.3%
survived 2 years or longer. Three factors could be identified as predictors of improved overall survival: absence of
lymph node metastasis (N0) (median OS 18.3 months), median dose of radiation of 50 Gy or more (median OS
10.5 months) and the use of any surgery (median OS 10.5 months).
Conclusions: Despite the generally poor outcome, the combination of surgery and intensive radiotherapy can
result in long-term survival in selected patients with ATC.
Keywords: Anaplastic thyroid cancer (ATC), Undifferentiated thyroid cancer (UTC), Radiotherapy, Multimodal
therapy, Prognostic factors, Long-term survivalBackground
Anaplastic thyroid cancer (ATC) is a highly malignant
tumor originating from follicle cells with a peak incidence
in the sixth to the seventh decade and preponderance in
women [1,2]. The WHO classification of thyroid cancer
distinguishes between the well-differentiated thyroid car-
cinoma (WDTC) - papillary and follicular - and undifferen-
tiated/anaplastic thyroid carcinoma (UTC, ATC). Poorly
differentiated thyroid carcinoma (PDTC), has been defined
as a histologic type inbetween these two groups [3].
ATC is known as one of the most serious malignant tu-
mors with a median overall survival of 6 months or less
[2-4]. It accounts for less than 5% of all thyroid cancer but
contributes up to 90% of thyroid cancer mortality [3].* Correspondence: dirk.vordermark@uk-halle.de
Department of Radiation Oncology, Martin Luther University
Halle-Wittenberg, Dryanderstr. 4, 06110 Halle (Saale), Germany
© 2014 Dumke et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orEach year, only about 420–900 new cases in Europe and
700–1200 new ATC patients in the USA are observed [5].
Patients usually present with a rapidly enlarging mass
and symptoms like stridor, dysphagia, vocal cord paralysis,
neck pain and dyspnea. Additionally in about half of ATC
patients there is evidence of metastatic disease at initial
diagnosis [1], the most common sites being lung, brain
and bone [6]. At the end of follow-up in most published
reports, the majority of patients have developed distant
metastasis [1,7].
The etiology of ATC is heterogeneous. It has been
found out, that genetic components as well as a lack of
iodine, radiation, female sex and nicotine abuses are im-
portant factors. Recent molecular pathological studies
elucidated the activation of various tyrosine cascades
and inactivation of the TP53 tumor suppressor gene.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Patients baseline characteristics (n = 40)
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long standing goiter [1,2,8].
As outlined in the recent American Thyroid Association
guidelines for the management of patients with anaplastic
thyroid cancer, there are so far no data from randomized
trials of ATC treatment available [9]. Treatment recom-
mendations must therefore be based on the experience
from case series, non-randomized trials and epidemiologic
databases. We, therefore, performed an analysis of long-
term results of radiotherapy in ATC patients treated at a
single center.At diagnosis 22.5%









Removal of lymph nodes 32.5%
Chemotherapy 15%
Radiotherapy: 97.5%
Opposing field technique 49.5%
3-d-conformal technique 14%
Combination of both 32.5%
Period between operation and radiation (in days/range) 13 (2–399)
Median applied dose (Gy/range) 50 (6–60.4)Methods
We performed a retrospective analysis of all 40 patients
(26 female, 14 male) who presented with histologically
proven ATC at the Dept. of Radiation Oncology, Martin
Luther University Halle-Wittenberg, Germany between
1989 and 2008. Information on patient and treatment
characteristics was systematically collected from the pa-
tients’ records. Survival status was determined for each pa-
tient via local registry offices. This retrospective analysis was
performed in compliance with the Helsinki Declaration.
The survival analysis was implemented by the software
Statistica (Version 10, Fa. Stat. Soft, Tulsa, OK, USA)
and used the Kaplan-Meier method. The endpoint in
this study was overall survival, where death of any cause
was considered an event. Patients alive at last follow-up
were censored. Overall survival for the whole cohort and
in subgroups defined by clinical and therapeutic factors
was calculated by the Kaplan-Meier method and com-
pared between subgroups using the log-rank test (p < 0.05
considered significant).Fractionation schedules
Daily radiation 87.5%
Twice daily radiation 7.5%
Radiation every second day 7.5%Results and discussion
Patient characteristics are presented in Table 1. In the
present cohort 65% of patients were female, the age
range was 38–84 years (median age 67). NO, N1 and N3
status were present in 23%, 40%, 3% (remainder Nx).
Distant metastases were reported in half of all cases,
25% at diagnosis, and another 25% in the course of treat-
ment (32.5% lung, 7.5% bone, 5% liver, 2.5% skin, 2.5% je-
junum, 2.5% mediastinum and 2.5% brain; multiple site
possible). In view of the long observation period each
tumour stage was assigned to the TNM classification valid
at the time of treatment (UICC 5th edition 1997 and 6th
edition 2002). If the current TNM classification (UICC 7th
edition 2009) is taken as a basis, a difference in lymph
node status results in 5 cases [10]. However, all ATC pa-
tients are stage IV in all versions.
After surgery which was accomplished in 80% of cases
(68% total, 12% subtotal thyroidectomy), only 10% of those
treated with surgery achieved a microscopic complete
resedction (R0). 50% had R2 status, 7.5% R1 status. In onethird of patients the resection status could not be deter-
mined. In 50%, a removal of lymph nodes was performed.
Six of 40 patients (15%) received any documented
chemotherapy, in three cases only before radiotherapy, in
one case only during radiotherapy, in one case only after
radiotherapy and in one case before, concomitant with and
following radiotherapy. The protocols used were adriblas-
tin monotherapy (two patients), paclitaxel monotherapy,
combination ifosfamide/carboplatin/etoposide, epirubicin
monotherapy and unknown protocol (one patient each). It
appears possible that further palliative chemotherapy may
have been given in some cases after radiotherapy in outside
institutions. In combination with surgery, radiotherapy was
always applied postoperatively.
Radiotherapy was delivered in 39 cases (one patient re-
fused radiotherapy). Various irradiation techniques were
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3D-conformal technique and in 32.5% cases a combin-
ation of both. Median total dose was 50 Gy (range 6 to
60.4 Gy). In 87.5% radiotherapy was given once daily, in
5% every other day and in 5% twice daily. In 8 patients
radiotherapy could not be completed because of deterior-
ation of general condition.
Target volume concepts varied. The most frequent com-
bination of anatomic locations for upper and lower border,
mastoid to tracheal bifurcation (+/−2 centimetres), was
applied in 27.6% of opposing-field techniques and 47% of
3D-conformal techniques. The distribution of upper and
lower field borders in relation to anatomic landmarks is
displayed in Figure 1.
CTCAE (version 3.0) skin toxicity was reported as grade
1, 2, or 3 in 28%, 45% and 13%, respectively. Grade 1, 2,
3 or 4 dysphagia was observed in 35%, 28%, 25% and 3%,
indicating that 28% of patients required tube feeding or
parenteral nutrition. During the course of treatment,
7 patients (18%) underwent emergency tracheotomy and
in 47.5% had recurrent laryngeal nerve palsy. During treat-
ment 8 patients (20%) suffered from acute dyspnea
attacks, one patient suffocated because of shortness of
breath and blood loss from the tracheostomy wound.
The median overall survival of all 40 patients was
5 months, 43.3% were alive at 6 months and 35.2% at one
year. Interestingly, 21.6% of patients survived 5 years or
longer after first presentation (Table 2, Figure 2). Three
significant factors were found to be predictors of higher
overall survival: absence of lymph node metastasis (N0),
median dose of radiation of 50 Gy or more and use ofOpposing-field
technique
(n=29)
Figure 1 Overview of anatomic positions of upper and lower field bo
techniques for anaplastic thyroid cancer (combinations of both technsurgery. Six months after presentation patients with sur-
gery had a median survival rate of 52.9%, in the compari-
son group however it was just 11.1%. Median survival of
patients who underwent a surgical intervention was
10.5 months vs. only 3 months without (p = 0.02, log-rank
test) (Figure 3A). A selection effect may be considered
since only patients in sufficient general condition were
candidates for surgery.
ATC patients without lymph node metastases (N0) had
a median survival of 18.3 months (Figure 3B); in the
comparison group it was significantly lower (4.5 months).
1-year and 5-year survival in the N0-collective was 75%
and 37.5%, patients with lymph node metastases had a cu-
mulative survival of 18.8% at both timepoints (p = 0.041).
ATC patients who received a total dose of 50 Gy or
more had a median survival of 10.5 months, whereas the
comparative group only survived 3 months. Cumulative
survival among patients irradiated to the higher doses
was 59.2%, 46.5% and 26.9% after 6 months, 1 year and
5 years, respectively; in the control group merely 22.5%,
16.8% and 11.2% (Figure 3C).
Non-significant trends toward improved survival were
observed for surgical removal of lymph nodes (p = 0.051)
and absence of distant metastasis (p = 0.07). No effects
were seen for resection status or use of chemotherapy.
We compared the nine patients with survival until last
follow-up with the rest of the cohort to obtain additional
information on potential prognostic factors. As expected
they were younger (median age: 64 vs. 69 years), less
often had lymph node metastasis (44.4% vs. 16.1%) and





thoracic vertebra 1 
tracheal bifurcation 
thoracic vertebra 11 
rders as used in opposing-field techniques and 3D-conformal
iques used in some patients).
Table 2 Survival of anaplastic thyroid cancer patients in
subgroups




Surgery Yes 10.5 0.02
No 3
N Stage N0 18.3 0.041
N+ 4.5
M Stage M0 18.3 0.07
M1 4
Age <67 years 5.5 0.39
≥67 years 4
Sex ♀ 5 0.66
♂ 5
Histology “Pure ATC” 4.5 0.29
“ATC with PDTC” 10.5
Total RT dose (Gy) ≥50 10.5 0.02
<50 3
Resection status R2 3.6 0.41
R0, R1 12.2
Lymph node dissection Yes 12.2 0.051
No 3
Chemotherapy Yes 4 0.85
No 5.5
Figure 2 Overall survival of n = 40 patients with histologically proven
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The presence of nine long-term survivors after treatment
of ATC in was an unexpectedly favorable result. It raised
the question, if all patients actually had ATC. Review of
histologic reports clearly confirmed that all patients were
diagnosed and treated as ATC. In view of recent changes
in histologic classification, we considered that some pa-
tients previously classified as ATC might be grouped as
poorly differentiated thyroid cancer (PDTC) in the current
classification. The presence of ATC within areas of tumor
types which would now be classified as PDTC (e.g. insular
carcinoma) was described in seven patients, whereas in
the remainder only ATC was described. The median sur-
vival was 10.5 months in patients with “ATC with PDTC”
vs. 4.5 months in patients with “pure ATC” (p = 0.29), sug-
gesting that – although all cases were clearly identifiably
as ATC and although the difference is not significant –
histologic subtypes may have contributed to differences in
survival.
Results of radiotherapy or multimodal therapy of ATC
have mostly been reported from retrospective studies
[11,12]. Though aggressive radiotherapy could reduce
locoregional recurrences, median overall survival did not
improve during the last 50 years [13]. In almost all ana-
lyses it was realized that only a multimodal therapy
consisting on surgery, radio- and possibly chemotherapy
is advisable since just one modality rarely leads to tumor
control, with combinations producing increased toxicity
[11,14]. Local control seems to be an important factor for
overall survival [11]. According to Levendag et al. [15]
who analyzed 51 patients treated over a period of 25 years
median survival under local control was 7.5 months, in
the group without local control just 1.6 months. In aanaplastic thyroid cancer.
AB
C
Figure 3 Overall survival in subgroups of patients with
anaplastic thyroid cancer: significantly improved survival was
seen in (A) patients with any surgery vs. no surgery (p = 0.02)
(B) patients with N0 status vs. N + status (p = 0.041) and
(C) patients with a radiotherapy dose of at least 50 Gy vs.
lower doses (p = 0.022).
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ceived three-phase-combined treatment complete re-
sponse after treatment was achieved in 14/44 patients
(31.8%), 8 had partial response (18.2%) and 22 (50%) had
progressive disease [11].In our collective as well as in other surveys more female
patients were affected (65% of cohort). The age structure
was similar to other studies, as ATC is a predominantly a
malignancy of the elderly. According an American review
of ATC [1], about 40% of patients at diagnosis had devel-
oped cervical lymph node metastases, which is synonym-
ous with significantly worse survival prognosis. This
perception corresponds to the proportion of lymph node
metastases in the present cohort (39%).Role of radiotherapy in ATC
In a Canadian study by Wang [16] there were 47 patients
and two therapy arms: Those with poor general condition
or distant metastasis were irradiated to a total dose of less
than 40 Gy (most often 20 Gy within one week), patients
with good general condition received radical therapy with
40 Gy or more (median 60 Gy). In the majority of cases
opposing-field technique was applied. Persons treated rad-
ically received 60 Gy in 30 fractions once daily within
6 weeks or in 40 fractions twice daily within 4 weeks.
Overall survival of patients irradiated with the higher dos-
age was 79.8% after 6 months, 46.1% after 1 year and 9.2%
after 2 years. In the group with palliative treatment, no pa-
tient survived longer than 9 months, 6-month survival
amounted to 16.7%. In this study, overall survival among
patients irradiated with 40 Gy or more was significantly
higher than in the comparison group: median 11.1 vs.
3.2 months (p < 0.0001) [16].
In a Swedish trial by Tennvall et al. [17] there was strong
correlation between accelerated radiotherapy and tumor
control. Patients who were irradiated twice a day with
1.6 Gy achieved local tumor control in 77.3%. However,
overall survival was disappointing (just 2 months versus 4.5
and 3.5 months). In the survey of Wang et al., median over-
all survival of patients irradiated twice daily was higher
(13.6 months) than of those irradiated once a day
(10.3 months). These results were not significant, therefore
the conclusion of hyperfractionation radiotherapy having
benefit on survival is considered cautiously by the authors
of this survey [16]. In a recent survey by Lim et al. in a col-
lective of 13 ATC patients the median overall survival was
longer with radical radiotherapy (11.1 months) compared
with palliative radiotherapy (3.2 months) [6].
Side effects of accelerated therapy and higher total
dosage must also be considered. In the present study,
skin toxicity and dysphagia of at least CTCAE grade 2
were each observed in more than half of the patients.
Planned total dose could not be achieved in eight cases.
According to a current review best success was achieved
with a dosage of at least 46 Gy [1]. This perception was
confirmed in the present study, as a total dose of 50 Gy
or more was a positive, statistically significant prognostic
factor for survival.
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Prophylactic tracheostomy has been identified as a contro-
versial factor by various authors. According to Wallin
et al. local tumour growth could be promoted by tracheos-
tomy and the start of radiotherapy might be delayed by
wound healing [14]. The percentage of distant metastasis
is high as well. According to Are et al. [1], 46% of patients
are affected at start of treatment, in the course of disease
the proportion increases to 68% (this cohort: 22.5% and
50%, respectively). In the largest ATC collective in the lit-
erature (516 patients of 12 population-based cancer regis-
tries of the USA, Kebebew et al. [18]) altogether 43% had
distant metastasis. Common sites of metastasis are lung
(up to 80%), bones (6-15%) and brain (5-13%) [6]. In 1996
Koboyashi et al. [19] found that by complete macroscopic
tumour resection an improvement of median survival
from 2 to 6 months could be achieved. A work of Junor
et al. [20] with 91 patients revealed that patients who
underwent a total or partial thyroidectomy with subse-
quent radiation survived longer than patients who had re-
ceived a biopsy only. Consequently, not the performance
of any surgical treatment but the extent of it is decisive.
Given the long time period of the present analysis (1989
to 2008), it is difficult to determine in individual cases
how the decision on surgical management was made. As
no interdisciplinary tumor board recommendation is
available for the vast majority of cases, it has to be as-
sumed that this was at the individual decision of the re-
sponsible surgeon, based on resectability, presence of
distant metastases and general condition of the patient.
Even in the most recent American Thyroid Association
Guidelines [9] the recommendations regarding surgery are
rather weak, essentially suggesting to “consider” resection
both in locoregional disease as well as in systemic disease.
Role of systemic therapy in ATC
Response rates of chemotherapeutic agents in ATC are
modest, in the range of 20% for doxorubicin, bleomycin,
etoposide, cisplatin and methotrexate. In a Swedish series
published in 2002, accelerated, hyperfractionated radio-
therapy and 20 mg doxorubicin given daily did not lead to
serious side effects [17]. The impact of chemotherapy on
survival is generally limited. One reason could be that ac-
cording in-vitro-analyses, anaplastic cell lines form less
mdr-1-mRNA and P-glycoprotein but more MRP (multi-
drug resistance-associated protein) which can expel cyto-
static agents from cells [1]. Chemotherapy has shown
beneficial effects mostly in combination with radiation.
Recently, molecular targeting strategies have been
evaluated in ATC. There have been efforts to develop
multikinase inhibitors to disturb signaling pathways
which are involved in the formation of undifferentiated
thyroid carcinoma and inhibitors of angiogenesis like
combretastatin [11]. Investigations have demonstratedthat the MMP-activated LeTx inhibited orthotopic ATC xe-
nografts progression in both toxin-sensitive and toxin-
resistant ATC cells via reduced endothelial cell recruitment
and subsequent tumour vascularization [21]. Other sys-
temic approach involves gefitinib which blocks the tyrosin-
kinase domain of the EGF receptor, which is often
overexpressed in ATC-cell lines [22] and monoclonal anti-
bodies against VEGF [23]. Other experimental studies have
focussed on BMP 7 (bone morphogenic protein) [7] inhibi-
tors of histone acetylases to augment the effect of cytostatic
drugs, PPAR-γ- (peroxisome proliferator-activated receptor
gamma) agonists like rosiglitazon and ciglitazone [22] and
bortezomib by inhibiting the NF-κB-pathway [24].Concomitant radiochemotherapy
Available data on the combination of radiotherapy and
chemotherapy (concomitant radiochemotherapy) are lim-
ited. In the current American Thyroid Association Guide-
lines [9], the following recommendation is made: “The use
of cytotoxic chemotherapy involving some combination of
taxane (paclitaxel or docetaxel), and/or anthracyclines
(doxorubicin) and/or platin (cisplatin or carboplatin) ther-
apy should be considered in combination with radiation
therapy or altered fractionated radiotherapy in good per-
formance status patients with nonmetastatic ATC who de-
sire aggressive therapy.” Thus, no specific protocol for
chemoradiation is recommended and the criteria for pa-
tient selection are not very clear. The recommendation is
based on single-institution experiences where consider-
able long-term survival (in the range of 30 to 50%) was
achieved in highly selected patients with locoregional dis-
ease (no distant metastases) who were treated with a tri-
modality regimen consisting of surgery (R0 oder R1),
high-dose radiotherapy and concomitant plus sequential
chemotherapy [25-27]; review in [28]. The chemotherapy
regimens used in these series were heterogeneous. The ex-
amples of “adjuvant/radiosensitizing chemotherapy” listed
in the 2012 American Thyroid Association Guidelines are
various regimens of monotherapies or doublet combina-
tions containing paclitaxel, cisplatin/carboplatin or doxo-
rubicin [9]. Due to the low number of patients receiving
any documented chemotherapy and especially receiving
chemotherapy concomitant with radiotherapy in the co-
hort studied now, no information on the optimal combin-
ation can be derived from our data set.Conclusions
Long-term single-center results of radiotherapy for ATC
indicate that despite a poor median survival of 5 months
in the overall cohort, 22% of patients could be regarded
as long-term survivors. A total radiation dose of >50 Gy,
any surgery and the absence of lymph node metastasis
were associated with improved survival.
Dumke et al. Radiation Oncology 2014, 9:90 Page 7 of 7
http://www.ro-journal.com/content/9/1/90Competing interests
The authors declare that they have no competing interests.Authors’ contributions
AD was involved in conception and design, acquisition, analysis and
interpretation of data and drafted the manuscript. TP made substantial
contributions to conception of the project, acquisition and analysis of data
and treated patients. DV contributed to conception, design, statistical
analysis and interpretation of data and revised the manuscript. All authors
have given final approval of the manuscript.
Received: 3 August 2013 Accepted: 16 March 2014
Published: 31 March 2014References
1. Are C, Ashok RS: Educational review anaplastic thyroid carcinoma:
biology, pathogenesis, prognostic factors, and treatment approaches.
Ann Surg Oncol 2006, 13:453–464.
2. Taccaliti A, Silvetti F, Palmonella G, Boscaro M: Anaplastic thyroid
carcinoma. Front Endocrinol 2012, 3:84.
3. Schmid KW: Pathogenese, klassifikation und histologie von
schilddrüsenkarzinomen. Onkologe 2010, 16:644–656.
4. Lim SM, Shin SJ, Chung WY, Park CS, Nam KH, Kang SW, Keum KC, Kim JH,
Cho JY, Hong YK, Cho BC: Treatment outcome of patients with anaplastic
thyroid cancer: a single center experience. Yonsei Med J 2012,
53(2):352–357.
5. Koussis H, Maruzzo M, Scola A, Eric CI, Fassina A, Marioni G, Lora O, Corti L,
Karachontziti P, Jirillo A: A case of anaplastic thyroid cancer with
long-term survival. Anticancer Res 2010, 30(4):1273–1278.
6. Lim KH, Lee KW, Kim JH, Park SY, Choi SH, Lee JS: Anaplastic thyroid
carcinoma initially presented with abdominal cutaneous mass and
hyperthyroidism. Korean J Intern Med 2010, 25(4):450–453.
7. Chang HS, Nam KH, Chung WY, Park CS: Anaplastic thyroid carcinoma:
a therapeutic dilemma. Yonsei Med J 2005, 46(6):759–764.
8. Sautter-Bihl ML, Reiners C: Schilddrüsenkarzinom. In Radioonkologie Band 2,
2. Aufl. Edited by Herausgegeben von Bamberg, Molls, Sack. München:
Zuckschwerdt-Verlag; 2009:281–293.
9. Smallridge RC, Ain KB, Asa SL, Bible KC, Brierly JD, Burman KD, Kebebew E,
Lee NY, Nikiforov YE, Rosenthal MS, Shah MH, Shaha AR, Tuttle RM:
American thyroid association guidelines for management of patients
with anaplastic thyroid cancer for the American thyroid association
anaplastic thyroid cancer guidelines taskforce. Thyroid 2012,
22(11):1104–1139.
10. Sobin LH, Gospodarowicz MK, Wittekind C: UICC TNM-classification of
malignant tumours. 7th edition. Oxford: Wiley-Blackwell; 2009.
11. Derbel O, Limem S, Ségura-Ferlay C, Lifante JC, Carrie C, Peix JL, Borson-
Chazot F, Bournaud C, Droz JP, de la Fouchardiére C: Results of combined
treatment of anaplastic thyroid carcinoma (ATC). BMC Cancer 2011,
11:469.
12. Segerhammar I, Larsson C, Nilsson IL, Bäckdahl M, Höög A, Wallin G,
Foukakis T, Zedenius J: Anaplastic carcinoma of the thyroid gland:
treatment and outcome over 13 years at one institution. J Surg Oncol
2012, 106(8):981–986.
13. Smallridge RC, Copland JA: Anaplastic thyroid carcinoma: pathogenesis
and emerging therapies. Clin Oncol (R Coll Radiol) 2010, 22(6):486–497.
14. Wallin G, Lundell G, Tennvall J: Anaplastic giant cell thyroid carcinoma.
Scand J Surg 2004, 93:272–277.
15. Levendag PC, Porre PM, de van Putten WL: Anaplastic carcinoma of the
thyroid gland treated by radiation therapy. Int J Radiat Oncol Biol Phys
1993, 1993(26):125–128.
16. Wang Y, Tsang R, Asa S, Dickson B, Arenovich T, Brierley J: Clinical outcome
of anaplastic thyroid carcinoma treated with radiotherapy of once- and
twice-daily fractionation regimens. Cancer 2006, 107(8):1786–1792.
17. Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Akerman M,
Hjelm-Skog AL, Wallin G: Anaplastic thyroid carcinoma: three protocols
combining doxorubicin, hyperfractionated radiotherapy and surgery.
Brit J Cancer 2002, 86(12):1848–1853.
18. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A: Anaplastic
thyroid carcinoma: treatment outcome and prognostic factors. Cancer
2005, 103:1330–1335.19. Kobayashi T, Asakawa H, Umeshita K, Takeda T, Maruyama H, Matsuzuka F,
Monden M: Treatment of 37 patients with anaplastic carcinoma of the
thyroid. Head Neck 1996, 18:36–41.
20. Junor EJ, Paul J, Reed NS: Anaplastic thyroid carcinoma: 91 patients
treated by surgery and radiotherapy. Eur J Surg Oncol 1992, 18(2):83–88.
21. Alfano RW, Leppla SH, Liu S, Bugge TH, Ortiz JM, Lairmore TC, Duesbery NS,
Mitchell IC, Nwariaku F, Frankel AE: Inhibition of tumor angiogenesis by
the matrix metalloproteinase-activated anthrax lethal toxin in an
orthotopic model of anaplastic thyroid carcinoma. Mol Cancer Ther 2010,
9(1):190–201.
22. Perri F, Di Lorenzo G, Della Vittoria Scarpati G, Buonerba C: Anaplastic
thyroid carcinoma: a comprehensive review of current and future
therapeutic options. World J Clin Oncol 2011, 2(3):150–157.
23. Matuszczyk A, Mann K: Neue Therapieformen beim Schilddrüsenkarzinom.
Onkologe 2010, 16(7):690–694.
24. Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J,
Fanourakis G, Tseleni-Balafouta S, Ain KB, Mitsiades N: Antitumor effects of
the proteasome inhibor bortezomib in medullary and anaplastic thyroid
carcinoma cells in vitro. J Clin Endocrinol Metab 2006, 91(10):4013–4021.
25. Besic N, Auersperg M, Us-Krasovec M, Golouh R, Frkovic-Grazio S, Vodnik A:
Effect of primary treatment on survival in anaplastic thyroid carcinoma.
Eur J Surg Oncol 2001, 27:260–264.
26. De Crevoisier R, Baudin E, Bachelot A, Leboulleux S, Travagli JP, Caillou B,
Schlumberger M: Combined treatment of anaplastic thyroid carcinoma
with surgery, chemotherapy, and hyperfractionated accelerated external
radiotherapy. Int J Radiat Oncol Biol Phys 2004, 60:1137–1143.
27. Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, Duh QY,
Clark OH: Completely resected anaplastic thyroid carcinoma combined
with adjuvant chemotherapy and irradiation is associated with
prolonged survival. Cancer 2001, 91:2335–2342.
28. Vordermark D, Pelz T, Sieker F: Die Rolle der externen Strahlentherapie bei
der Behandlung des Schilddrüsenkarzinoms. Onkologe 2010, 16:695–700.
doi:10.1186/1748-717X-9-90
Cite this article as: Dumke et al.: Long-term results of radiotherapy in
anaplastic thyroid cancer. Radiation Oncology 2014 9:90.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
